Glomerulonephritis, Membranous
16
1
1
10
Key Insights
Highlights
Success Rate
91% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 17/100
6.3%
1 terminated out of 16 trials
90.9%
+4.4% vs benchmark
50%
8 trials in Phase 3/4
50%
5 of 10 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 10 completed trials
Clinical Trials (16)
Mycophenolate Mofetil in Patients With Progressive Idiopathic Membranous Nephropathy
Trial to Assess Safety and Efficacy of MOR202 in Anti-PLA2R + Membranous Nephropathy (aMN)
Clinical Study of Rituximab for the Treatment for Idiopathic Membranous Nephropathy with Nephrotic Syndrome
The Influencing Factors and Mechanism of High Incidence of Thrombotic Events in Patients With MN and DKD
Application of Hyperspectral Imaging in the Diagnosis of Glomerular Diseases
Mycophenolate Mofetil and Tacrolimus Versus Tacrolimus for the Treatment of Idiopathic Membranous Glomerulonephritis
Rituximab in Refractory Primary Membranous Nephropathy
Rituximab Versus Steroids and Cyclophosphamide in the Treatment of Idiopathic Membranous Nephropathy
Research Network for Neonatal Diseases Induced by Tissular Fetomaternal Alloimmunization
A Study of Belimumab in Idiopathic Membranous Glomerulonephropathy
Efficacy and Safety Study of Intravenous Belimumab Versus Placebo in Subjects With Idiopathic Membranous Nephropathy
Aldosterone Breakthrough During Diovan, Tekturna, and Combination Therapy in Patients With Proteinuric Kidney Disease
Treatment of Patients With Idiopathic Membranous Nephropathy
A Study to Compare Mycophenolate Mofetil and Tacrolimus in the Treatment of Membranous Lupus Nephritis
Mycophenolate Mofetil in Membranous Nephropathy and Focal Segmental
Mycophenolate Mofetil in Membranous Nephropathy